Evidence map›Paper›PMID 30565087›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

Citron kinase (CIT-K) promotes aggressiveness and tumorigenesis of breast cancer cells in vitro and in vivo: preliminary study of the underlying mechanism.

D Meng, Q Yu, L Feng, M Luo, S Shao, S Huang, G Wang, X Jing, Z Tong, X Zhao and 1 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

D MengDepartment of Oncology, First Affiliated Hospital of Medical School of Xi'an Jiaotong University, 277# Yanta west Road, Xi'an, 710061, Shaanxi, People's Republic of China.
Q YuDepartment of Oncology, First Affiliated Hospital of Medical School of Xi'an Jiaotong University, 277# Yanta west Road, Xi'an, 710061, Shaanxi, People's Republic of China.
L FengDepartment of Oncology, First Affiliated Hospital of Medical School of Xi'an Jiaotong University, 277# Yanta west Road, Xi'an, 710061, Shaanxi, People's Republic of China.
M LuoDepartment of Oncology, First Affiliated Hospital of Medical School of Xi'an Jiaotong University, 277# Yanta west Road, Xi'an, 710061, Shaanxi, People's Republic of China.
S ShaoDepartment of Oncology, First Affiliated Hospital of Medical School of Xi'an Jiaotong University, 277# Yanta west Road, Xi'an, 710061, Shaanxi, People's Republic of China.
S HuangDepartment of Oncology, First Affiliated Hospital of Medical School of Xi'an Jiaotong University, 277# Yanta west Road, Xi'an, 710061, Shaanxi, People's Republic of China.
G WangDepartment of Oncology, First Affiliated Hospital of Medical School of Xi'an Jiaotong University, 277# Yanta west Road, Xi'an, 710061, Shaanxi, People's Republic of China.
X JingDepartment of Oncology, First Affiliated Hospital of Medical School of Xi'an Jiaotong University, 277# Yanta west Road, Xi'an, 710061, Shaanxi, People's Republic of China.
Z TongSchool of Mechanical Engineering, Xi'an Jiaotong University, Xi'an, 710049, Shaanxi, People's Republic of China.
X ZhaoDepartment of Oncology, First Affiliated Hospital of Medical School of Xi'an Jiaotong University, 277# Yanta west Road, Xi'an, 710061, Shaanxi, People's Republic of China. zhaoxinhanprof@163.com.
R LiuDepartment of Oncology, First Affiliated Hospital of Medical School of Xi'an Jiaotong University, 277# Yanta west Road, Xi'an, 710061, Shaanxi, People's Republic of China. reon10@sina.com.ORCID http://orcid.org/0000-0001-9886-949X
First Affiliated Hospital of Xi'an Jiaotong University · CNFuyang City People's Hospital · CNXi'an Jiaotong University · CN

Funding

Basic Research Funds Project of Xi'an Jiaotong University 10120121101
6 · The paper itself

Abstract

objectivesCitron kinase (CIT-K), as a key Rho effector, functions to maintain proper structure of the midbody during cell mitosis. This study assessed CIT-K expression and its role in breast cancer cells.

methodsParaffin-embedded breast cancer and para-tumor tissues from 43 invasive breast cancer patients and 33 normal mammary glands were collected for immunohistochemistry. CIT-K expression knockdown was achieved using lentivirus carrying CIT-K shRNA in a wide range of breast cancer cell lines. Cells were then subjected to Western blot, qRT-PCR, cell proliferation, colony formation, transwell, and flow cytometric assays. The tumorigenicity of CIT-K knocked-down breast cancer cells was assessed using the nude mouse xenograft assay. Microarray analysis was performed to elucidate the underlying gene regulation after CIT-K silencing.

resultsCIT-K protein was overexpressed in breast cancer tissues, which is associated with advanced tumor stage, HER-2 expression and Ki-67 expression, whereas knockdown of CIT-K expression reduced breast cancer cell proliferation and colony formation, but promoted tumor cell apoptosis and cell-cycle arrest. Knockdown of CIT-K expression also inhibited breast cancer cell migration and invasion capacity. Moreover, CIT-K knockdown suppressed the tumorigenicity of breast cancer cells in nude mice. Molecularly, the expression of a variety of signaling genes, such as cyclin D1, EGFR, JAK1, TGF-α, PTK2, RAF1, RALB, SOS1, mTOR, and PTGS2, were altered after CIT-K knockdown.

conclusionsThis study demonstrated that CIT-K is associated with aggressive breast cancer behavior and targeting CIT-K may be a novel strategy for the future control of breast cancer.

Indexed as

Cell ProliferationAnimalsBiomarkers, TumorBreast NeoplasmsCase-Control StudiesCell CycleCell MovementCell Transformation, NeoplasticFemaleGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsIn Vitro TechniquesMice, Inbred NODMice, SCIDMiddle AgedBiomarkers, Tumorcitron-kinaseIntracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesBreast cancerCIT-KGene knockdownTumorigenicity

Identifiers

PMID30565087
OpenAlexW2903586761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.